Journals / Anadolu Kardiyoloji Dergisi / 2003 / Cilt: 3 - Sayı: 4

Assessment of the efficacy of bisoprolol administration by cardiopulmonary exercise testing in patients with heart failure

Kalp yetersizliğinde bisoprolol tedavi etkinliğinin kardiyopulmoner egzersiz testi ile değerlendirilmesi

Pages
313–318
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: We found a significant increase in exercise duration, maximal O2 uptake (pik VO2 ), the O2 uptake at the anaerobic threshold (VO2-AT) and O2-pulse (pik VO2/ HR), and improved functional capacity (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: It is well known that long-term therapy with beta-blockers reduces morbidity and mortality, improves left ventricular function in patients with heart failure.
📊
Key Findings & Data:Methods: We enrolled 52 patients (mean age 59±11 years) with stable, mild to moderate chronic heart failure and left ventricular ejection fraction of %40 or less receiving standart therapy with diuretic and ACE inhibitor.
💡
Conclusion & Impact:Results: We found a significant increase in exercise duration, maximal O2 uptake (pik VO2 ), the O2 uptake at the anaerobic threshold (VO2-AT) and O2-pulse (pik VO2/ HR), and improved functional capacity (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: It is well known that long-term therapy with beta-blockers reduces morbidity and mortality, improves left ventricular function in patients with heart failure. However the effect of beta-blockade on exercise tolerance in patients with heart failure remains unclear. In the present study we evaluated effects of the addition of bisoprolol to standart therapy with a diuretic and an angiotensin converting enzyme (ACE) inhibitor on exercise capacity in patients with chronic heart failure. Methods: We enrolled 52 patients (mean age 59±11 years) with stable, mild to moderate chronic heart failure and left ventricular ejection fraction of %40 or less receiving standart therapy with diuretic and ACE inhibitor. We randomly assigned patients to bisoprolol 1.25 mg (n=28) or control (n=24) groups. The drug progressively increased to a maximum dose of 5 mg per day. Cardiopulmonary exercise testing (CPET) was performed in all patients of the bisoprolol and control groups before and after 3 months from the beginning of the study. Results: We found a significant increase in exercise duration, maximal O2 uptake (pik VO2 ), the O2 uptake at the anaerobic threshold (VO2-AT) and O2-pulse (pik VO2/ HR), and improved functional capacity (p

Özet

Amaç: Beta blokerlerin kalp yetersizliğinde morbidite ve mortaliteyi azalttığı, sol ventrikül ejeksiyon fraksiyonunu (SVEF) iyileştirdiği bilinmektedir. Fakat fonksiyonel kapasite üzerine olan etkileri kesinlik kazanmamıştır. Bu çalışmada, kronik kalp yetersizliğinde (KKY) standart tedaviye bisoprolol ilave edilmesinin egzersiz kapasitesine olan etkisini değerlendirmeyi amaçladık. Yöntem: Hafif-orta derecede KKY tanısı ile izlenen, SVEF %40 ya da daha düşük olan, diüretik ve anjiyotensin dönüştürücü enzim (ACE) inhibitöründen oluşan standart tedaviyi alan, klinik olarak stabil olan, 52 hasta (ortalama yaş 59±11 yıl) çalışmaya dahil edildi. Bu hastalar randomize olarak bisoprolol (n=28) ve kontrol (n=24) grubuna ayrıldı. Bisoprolol tedavisi başlangıçta 1.25 mg/gün uygulandı, dozaj kan basıncı ve nabız takibine göre haftada bir artırılarak, maksimum 5 mg/gün düzeyine ulaşıldı ve üç ay süre ile aynı tedaviye devam edildi. Kontrol grubundaki hastaların tedavisi üç ay süre ile değiştirilmedi. Hastalara çalışmanın başında ve üçüncü ay sonunda kardiyopulmoner egzersiz testi (KPET) uygulandı. Bulgular: Standart tedaviye bisoprolol ilavesi ile egzersiz süresinde, maksimal oksijen tüketimde (pik VO2), anaerobik eşikteki O2 (AT-VO2 ) değerinde ve maksimal O2-pulse (pik VO2/HR) değerinde anlamlı derecede artma, fonksiyonel kapasitede anlamlı derecede düzelme tespit edildi (p

🔖

Cite This Article

SAYAR, N., TERZİ, S., AKSOY, Ş., KÖSE, H., ŞATIROĞLU, Ö., BİLSEL, T., AKBULUT, T., YEŞİLÇİMEN, K., DAYİ, Ü. Ş., DAĞ, Ö. (2022). Assessment of the efficacy of bisoprolol administration by cardiopulmonary exercise testing in patients with heart failure. Anadolu Kardiyoloji Dergisi, Cilt: 3 - Sayı: 4, 313–318. https://ajindex.com/articles/437544

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 85: 790-804
  2. Esler M, Kaye D, Lambert G, at al. Adrenergic nervous system in heart failure. Am J Cardiol 1997; 80: 71-141
  3. Tan L, Jalil JE, Pick R, Janicki LS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69: 1185-95
  4. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
  5. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet 1999; 353: 9-13
  6. Olsen SL, Gilbert EM, Renlund DG, Tylor DO, Yanowitz FD. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995; 25: 1225-31
  7. Bristow MR. B-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-69
  8. Wasserman K, Hansen JE, Sue DY, Whipp BJ, Casaburi R: Principles of exercise testing and interpretation. Lea & Febiger; 1994. p. 53-111. Philadelphia
  9. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358-67
  10. Kim MH, Devlin WH, Das SK, Petrusha J, Montgomery D. Effects of B-adrenergic blocking therapy on left ventricular diastolic relaxation properties in patients with dilated cardiomyopathy. Circulation 1999; 100: 729-35
  11. Dubach P, Myers J, Bonetti P, et al. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J 2002; 143: 676-83
  12. Zotz SG, Zotz RJ, Sigmund M, et al. MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. Eur J Heart Failure 2000; 2: 175-81
  13. The cardiac insufficiency bisoprolol study (CIBIS): a randomized trial of B-blockade in heart failure. Circulation 1994; 90: 1765-73
  14. Kukin ML, Kalman J, Charney RH. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999; 99: 2645-51
  15. Australia New Zeland Heart Failure Research Collaborative Group. Effect of carvedilol a vasod